Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
- BLA submission for AT132 for the treatment of XLMTM on-track for mid-2020; MAA on-track for second half of 2020 - Continued progress in Pompe Disease, DMD and DM1 pipeline programs: AT845 IND submitted and clinical start-up activities underway; AT702 IND on track for first quarter 2020 submission
Toggle Summary Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 31, 2019-- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its
Toggle Summary Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society
- First seven treated patients now ventilator independent and able to rise to a standing position or walk   - Continued significant and durable improvements in respiratory function and developmental motor milestones in all treated patients   - AT132 continues to be generally well-tolerated with a
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  SAN FRANCISCO --(BUSINESS WIRE)--Oct. 4, 2019-- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards that were
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
  SAN FRANCISCO --(BUSINESS WIRE)--Oct. 1, 2019-- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles , President and
Toggle Summary Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)
- Oral presentation of ASPIRO results to include additional efficacy and safety data on all patients in dose Cohort 1 and the first treated patients in dose Cohort 2   - Additional presentations include data from INCEPTUS, a prospective natural history run-in study to characterize the clinical
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 6, 2019-- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards that were
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Aug. 26, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the following
Toggle Summary Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Commenced enrollment of 8 patients into an ASPIRO pivotal expansion cohort to confirm the safety and efficacy profile of AT132 for the treatment of X-linked myotubular myopathy (XLMTM) at dose of 3x10 14 vg/kg - Biologics License Application (BLA) submission for AT132 planned in mid-2020;
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Aug. 1, 2019 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the following